BioCentury
ARTICLE | Financial News

Spectrum raises $90M in at-the-market offering

September 29, 2017 9:56 PM UTC

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it raised $90.2 million since Aug. 11 in an at-the-market offering through the sale of about 9.3 million shares.

Last year, Spectrum received a complete response letter from FDA for and NDA for Qapzola apaziquone to treat non-muscle invasive bladder cancer (NMIBC). In August, the biotech began a Phase III trial of the candidate to treat NMIBC. Qapzola is an analog of mitomycin C that is reduced by intracellular reductases into active DNA-damaging moieties (see BioCentury Extra, Nov. 18, 2016)...

BCIQ Company Profiles

Spectrum Pharmaceuticals Inc.